Copy to clipboard 
Amphix Bio secured a $1 million Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation (NSF) to scale up manufacturing methods for its platform technology. The platform is based on supramolecular peptide therapeutics that signal the patient’s own cells to initiate regenerative processes.
The manufacturing technology developed with the grant funds will be used to produce an off-the-shelf implant for spinal fusion surgeries. This product was recently designated as a Breakthrough Device by FDA for treating back pain caused by degenerative disc disease. In its Phase I project, Amphix Bio developed new manufacturing methods for its bone regeneration therapy and created a moldable, putty-like formulation that demonstrated efficacy in large animal models. The goals of the Phase II project are to scale up production of the company’s therapeutic peptides, develop new manufacturing methods for the putty formulation, and complete biocompatibility testing.
At the end of the project, the company plans to produce final-packaged, end-sterilized spine implants validated in large animal studies, the final step before beginning clinical trials.
“We are grateful to the NSF for this Phase II funding and are excited to advance our manufacturing capabilities to bring the supramolecular therapeutics platform into the clinic,” said Amphix Bio co-founder and CEO Nick Sather, PhD. “Our technology can offer a simpler and safer solution for treating debilitating back pain, without the side effects associated with harvesting autograft tissue or using recombinant proteins to induce bone growth.”
The grant brings the company’s total SBIR funding to $1.25 million. In addition to the SBIR grant, the company recently received non-dilutive funding from the Illinois Science and Technology Coalition aimed at supporting innovation in the state. These grants will expand Amphix Bio’s long-running collaborations at Northwestern University.
Source: Amphix Bio
Amphix Bio secured a $1 million Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation (NSF) to scale up manufacturing methods for its platform technology. The platform is based on supramolecular peptide therapeutics that signal the patient's own cells to initiate regenerative processes.
The manufacturing...
Amphix Bio secured a $1 million Small Business Innovation Research (SBIR) Phase II grant from the National Science Foundation (NSF) to scale up manufacturing methods for its platform technology. The platform is based on supramolecular peptide therapeutics that signal the patient’s own cells to initiate regenerative processes.
The manufacturing technology developed with the grant funds will be used to produce an off-the-shelf implant for spinal fusion surgeries. This product was recently designated as a Breakthrough Device by FDA for treating back pain caused by degenerative disc disease. In its Phase I project, Amphix Bio developed new manufacturing methods for its bone regeneration therapy and created a moldable, putty-like formulation that demonstrated efficacy in large animal models. The goals of the Phase II project are to scale up production of the company’s therapeutic peptides, develop new manufacturing methods for the putty formulation, and complete biocompatibility testing.
At the end of the project, the company plans to produce final-packaged, end-sterilized spine implants validated in large animal studies, the final step before beginning clinical trials.
“We are grateful to the NSF for this Phase II funding and are excited to advance our manufacturing capabilities to bring the supramolecular therapeutics platform into the clinic,” said Amphix Bio co-founder and CEO Nick Sather, PhD. “Our technology can offer a simpler and safer solution for treating debilitating back pain, without the side effects associated with harvesting autograft tissue or using recombinant proteins to induce bone growth.”
The grant brings the company’s total SBIR funding to $1.25 million. In addition to the SBIR grant, the company recently received non-dilutive funding from the Illinois Science and Technology Coalition aimed at supporting innovation in the state. These grants will expand Amphix Bio’s long-running collaborations at Northwestern University.
Source: Amphix Bio
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
